CN101068533B - 含有抗成核剂的药物组合物 - Google Patents

含有抗成核剂的药物组合物 Download PDF

Info

Publication number
CN101068533B
CN101068533B CN2005800415795A CN200580041579A CN101068533B CN 101068533 B CN101068533 B CN 101068533B CN 2005800415795 A CN2005800415795 A CN 2005800415795A CN 200580041579 A CN200580041579 A CN 200580041579A CN 101068533 B CN101068533 B CN 101068533B
Authority
CN
China
Prior art keywords
weight
compound
pharmaceutical composition
amount
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800415795A
Other languages
English (en)
Chinese (zh)
Other versions
CN101068533A (zh
Inventor
M·T·克吕安斯
W·徐
L·M·阿蒂诺
H·朱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36565788&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101068533(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN101068533A publication Critical patent/CN101068533A/zh
Application granted granted Critical
Publication of CN101068533B publication Critical patent/CN101068533B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2005800415795A 2004-12-03 2005-12-02 含有抗成核剂的药物组合物 Expired - Fee Related CN101068533B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63285904P 2004-12-03 2004-12-03
US60/632,859 2004-12-03
PCT/US2005/043675 WO2006060681A2 (en) 2004-12-03 2005-12-02 Pharmaceutical composition containing an anti-nucleating agent

Publications (2)

Publication Number Publication Date
CN101068533A CN101068533A (zh) 2007-11-07
CN101068533B true CN101068533B (zh) 2011-04-27

Family

ID=36565788

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800415795A Expired - Fee Related CN101068533B (zh) 2004-12-03 2005-12-02 含有抗成核剂的药物组合物

Country Status (9)

Country Link
US (1) US8771733B2 (enExample)
EP (2) EP1819323B2 (enExample)
JP (3) JP2008521929A (enExample)
CN (1) CN101068533B (enExample)
AU (1) AU2005311714B2 (enExample)
CA (1) CA2588465C (enExample)
ES (1) ES2727577T5 (enExample)
TR (1) TR201907729T4 (enExample)
WO (1) WO2006060681A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070085702A (ko) * 2004-12-03 2007-08-27 머크 앤드 캄파니 인코포레이티드 Ｕｇｔ1ａ1에 의해 대사된 약물의 약력학을 개선시키기위한 아타자나비르의 용도
UA87884C2 (uk) 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Безводна кристалічна калієва сіль інгібітора віл-інтегрази
WO2006060711A2 (en) 2004-12-03 2006-06-08 Merck & Co., Inc. Pharmaceutical formulation of carboxamide hiv integrase inhibitors containing a release rate controlling composition
EP1819323B2 (en) 2004-12-03 2023-03-22 Merck Sharp & Dohme Corp. Pharmaceutical composition containing an anti-nucleating agent
ES2744816T3 (es) * 2006-10-27 2020-02-26 Capsugel Belgium Nv Cápsulas duras de hidroxipropil metil celulosa y proceso de fabricación
CN101197832B (zh) * 2007-12-13 2012-01-25 华为技术有限公司 一种实现iptv业务的方法、系统、装置
ES2549387T3 (es) 2009-06-02 2015-10-27 Hetero Research Foundation Procedimiento de preparación de raltegravir potásico amorfo
EP3970702A1 (en) 2009-10-26 2022-03-23 Merck Sharp & Dohme Corp. Solid pharmaceutical compositions containing an integrase inhibitor
JP5889275B2 (ja) 2010-04-01 2016-03-22 テバ ファーマシューティカル インダストリーズ リミティド ラルテグラビル塩およびその結晶形
US9968607B2 (en) 2011-04-25 2018-05-15 Hetero Research Foundation Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof
US12472475B2 (en) 2018-02-02 2025-11-18 The General Hospital Corporation Methods of supercooling aqueous samples
US12465565B2 (en) 2020-01-23 2025-11-11 Lupin Limited Pharmaceutical compositions of raltegravir
US20230277587A1 (en) * 2022-03-03 2023-09-07 Dermacisen, S.A. Food supplement for oral administration

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6369094B1 (en) * 1999-09-28 2002-04-09 Pfizer Inc. Polymorphic salt
WO2003035077A1 (en) * 2001-10-26 2003-05-01 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540566A (en) * 1984-04-02 1985-09-10 Forest Laboratories, Inc. Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose
JPH0347124A (ja) * 1989-04-20 1991-02-28 Fujisawa Pharmaceut Co Ltd 経口吸収用製剤
CA2019324C (en) * 1989-07-10 1996-08-20 Robert L. Jerzewski Fosinopril tablet formulations
JP2707023B2 (ja) * 1992-07-01 1998-01-28 株式会社大塚製薬工場 経口吸収用製剤
AU6329599A (en) † 1998-09-28 2000-04-17 Glaxo Group Limited Antiviral combinations comprising (s)-2-ethyl -7-fluoro -3-oxo-3, 4-dihydro -2h-quinoxaline -1-carboxylic acid isopropyl ester
US6620841B1 (en) * 1998-12-25 2003-09-16 Shionogi & Co., Ltd. Aromatic heterocycle compounds having HIV integrase inhibiting activities
JP5230050B2 (ja) * 2000-05-08 2013-07-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｈｉｖ複製阻害剤
US7115565B2 (en) † 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
DK1441734T3 (da) * 2001-10-26 2007-06-11 Angeletti P Ist Richerche Bio Dihydroxypyrimidin-carboxamid-inhibitorer a HIV-integrase
WO2003086319A2 (en) 2002-04-10 2003-10-23 Merck & Co., Inc. Pharmaceutical compositions containing an hiv integrase inhibitor and a nonionic surfactant
KR20050087865A (ko) 2002-12-27 2005-08-31 이스티투토 디 리세르쉐 디 비올로지아 몰레콜라레 피. 안젤레티에스.피.에이. ＨＩＶ 인테그라제 억제제로서 유용한테트라하이드로-4Ｈ-피리도[1,2-ａ]피리미딘 및 관련화합물
US20040224917A1 (en) † 2003-01-14 2004-11-11 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
KR20070085702A (ko) 2004-12-03 2007-08-27 머크 앤드 캄파니 인코포레이티드 Ｕｇｔ1ａ1에 의해 대사된 약물의 약력학을 개선시키기위한 아타자나비르의 용도
WO2006060711A2 (en) † 2004-12-03 2006-06-08 Merck & Co., Inc. Pharmaceutical formulation of carboxamide hiv integrase inhibitors containing a release rate controlling composition
EP1819323B2 (en) 2004-12-03 2023-03-22 Merck Sharp & Dohme Corp. Pharmaceutical composition containing an anti-nucleating agent
UA87884C2 (uk) * 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Безводна кристалічна калієва сіль інгібітора віл-інтегрази
US9968607B2 (en) 2011-04-25 2018-05-15 Hetero Research Foundation Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6369094B1 (en) * 1999-09-28 2002-04-09 Pfizer Inc. Polymorphic salt
WO2003035077A1 (en) * 2001-10-26 2003-05-01 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase

Also Published As

Publication number Publication date
EP1819323B2 (en) 2023-03-22
EP1819323A4 (en) 2012-07-18
JP2012184250A (ja) 2012-09-27
EP3165220A1 (en) 2017-05-10
WO2006060681A3 (en) 2006-10-12
EP3165220B1 (en) 2019-04-03
EP3165220B2 (en) 2024-11-13
CN101068533A (zh) 2007-11-07
TR201907729T4 (tr) 2019-06-21
JP2013063999A (ja) 2013-04-11
EP1819323B1 (en) 2016-11-16
AU2005311714B2 (en) 2010-09-30
US8771733B2 (en) 2014-07-08
ES2727577T3 (es) 2019-10-17
EP1819323A2 (en) 2007-08-22
JP2008521929A (ja) 2008-06-26
US20080118559A1 (en) 2008-05-22
CA2588465C (en) 2013-10-01
CA2588465A1 (en) 2006-06-08
ES2727577T5 (en) 2025-04-02
WO2006060681A2 (en) 2006-06-08
AU2005311714A1 (en) 2006-06-08

Similar Documents

Publication Publication Date Title
JP2012184250A (ja) 抗核形成剤を含有する医薬組成物
IL183615A (en) Pharmaceutical formulation of HIV carboxamide amide-containing inhibitors containing the controlled-release composition
AU2023274142B2 (en) Crystal
WO2007087188A2 (en) Taste-masked tablets and granules
AU2005311672B2 (en) Use of atazanavir for improving the pharmacokinetics of drugs metabolized by UGT1A1
WO2009123169A1 (ja) アミド誘導体含有医薬組成物
JP2013543495A (ja) 強力なｈｃｖインヒビターの固体形体
KR20190090729A (ko) 토파시티닙의 신규 염, 이의 제조방법 및 이를 포함하는 약학 조성물
KR20160146428A (ko) 솔리페나신 또는 그의 약학적으로 허용되는 염과 락토즈를 포함하는 안정한 무정형 솔리페나신 약학 조성물 및 그의 제조방법

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: SCHERING CORP (US)

Free format text: FORMER OWNER: MSD CORP.

Effective date: 20121031

C41 Transfer of patent application or patent right or utility model
C56 Change in the name or address of the patentee

Owner name: MSD CORP.

Free format text: FORMER NAME: SCHERING CORP (US)

CP01 Change in the name or title of a patent holder

Address after: New jersey, USA

Patentee after: MERCK SHARP & DOHME Corp.

Address before: New jersey, USA

Patentee before: SCHERING Corp.

TR01 Transfer of patent right

Effective date of registration: 20121031

Address after: New jersey, USA

Patentee after: SCHERING Corp.

Address before: New jersey, USA

Patentee before: MERCK SHARP & DOHME Corp.

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110427

Termination date: 20131202